eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
2/2022
vol. 38
 
Share:
Send email
Share:
Review article

Biomarkers of the central nervous system injury in Wilson’s disease

Agnieszka Antos
1
,
Tomasz Litwin
1
,
Adam Przybyłkowski
2
,
Jan Bembenek
1
,
Marta Skowrońska
1
,
Iwona Kurkowska-Jastrzębska
1
,
Łukasz Smoliński
1
,
Anna Członkowska
1

  1. 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
  2. Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Poland
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (2), 119–139
DOI: https://doi.org/10.5114/fpn.2022.123246
Online publish date: 2022/12/28
Article file
- C01R_IPiN_FARM_2022-2B.pdf  [1.96 MB]
Get citation
 
PlumX metrics:
 
1. Alanen A, Komu M, Pentinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson’s disease. Brit J Radiol 1999; 72: 749-756.
2. Antos A, Litwin T, Skowrońska M, Kurkowska-Jastrzębska I, Członkowska A. Diagnostyka choroby Wilsona – aktualne zalecenia. Polski Przegląd Neurologiczny 2020: 16: 209-222. (a)
3. Antos A, Litwin T, Skowrońska M, Kurkowska-Jastrzębska I, Członkowska A. Leczenie choroby Wilsona – aktualne zalecenia. Polski Przegląd Neurologiczny 2020; 16: 223-238. (b)
4. Antos A, Litwin T, Skowrońska M, Kurkowska-Jastrzębska I, Członkowska A. Perspektywy leczenia choroby Wilsona. Farmakoterapia w Psychiatrii i Neurologii 2021; 37: 155-167.
5. Aggarval A, Aggarval N, Nagral A, Jankharia G, Bhatt M. A novel global assessment scale for Wilson’s disease (GAS for WD). Mov Disord 2009; 24: 509-518.
6. Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141: 2382-2391.
7. Beinhardt S, Leiss W, Stattermayer AF, Graziadei I, Zoller H, Stauber R et al. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol 2014; 12: 683-689.
8. Bost M, Houdart S, Oberli M, Kalonji E, Huneau JF, Margaritis I. Dietetary copper and human health: Current evidence and unresolved issues. Journal of Trace Elements in Medicine and Biology 2016; 35: 107-115.
9. Bruha R, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011; 31: 83-91.
10. da Costa M, Spitz M, Bacheschi LA, Leite CC, Lucato LT, Barbosa ER. Wilson’s disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI. Neuroradiology 2009; 51: 627-633.
11. Członkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M. Wilson’s disease – cause of mortality in 164 patients during 1992–2003 observation period. J Neurol 2005; 252: 698-703.
12. Członkowska A, Tarnacka B, Möller JC, Leinweber B, Bandmann O, Woimant F et al. Unified Wilson’s Disease Rating Scale – proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol 2007; 41:1-12.
13. Czlonkowska A, Litwin T. Wilson disease – currently used anticopper therapy. In: Handb. Clin Neurol, Wilson disease. Członkowska A, Schilsky ML (ed.), 2017; 142: 181-91.
14. Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V et al. Wilson disease. Nat Rev Dis Primers. 2018; 4: 21. (a)
15. Członkowska A, Litwin T, Dzieżyc K, Karliński M, Bring J, Bjartmar C. Characteristic of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson’s Disease Rating Scale. BMC Neurol 2018; 18: 34. (b)
16. De Lorenzo R, Loré NI, Finardi A, Mandelli A, Cirillo DM, Tresoldi C et al. Blood neurfilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol 2021; 268: 4436-4442.
17. Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857-70.
18. Dusek P, Smoliński L, Redzia-Ogrodnik B, Golebiowski M, Skowronska M, Poujois A et al. Semiquantitative scale for assessing brain MRI abnormalities in Wilson disease: a validation study. Mov Disord 2020; 35: 994-1001.
19. EASL. European Association For The Study of The Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol 2012; 56: 671-85.
20. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-42.
21. Gaetani L, Parnetti L. NfL as analogue of C-reactiv protein in neurologic diseases. Instructions for use. Neurology 2022; 98: 911-912.
22. Gao YL, Wang N, Sun FR, Cao XP, Zhang W, Yu JT. Tau in neurodegenerative disease. Ann Transl Med. 2018; 6: 175.
23. Goedert M. Tau filaments in neurodegenerative disease. FEBS Letters 2018; 592: 2383-2391.
24. Josephs KA. Current understanding of neurodegenerative disease associated with the protein tau. Mayo Clin Proc 2017; 92: 1291-1303.
25. Kalita J, Kumar V, Parashar V, Misra UK. Neuropsychiatric manifestations of Wilson’s disease: correlation with MRI and glutamate exicotoxicity. Molecular Neurobiology 2021; 58: 6020-6031.
26. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14: 577-89.
27. King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID et al. Cranial MR imaging in Wilson’s disease, AJR Am J Roentgenol 1996; 167: 1579-1584.
28. Kozić D, Svetel M, Petrović B, Dragasević N, Semnic R, Kostić VS. MR imaging of the brain in patients with hepatic form of Wilson’s disease. Eur J Neurol 2003; 10: 587-592.
29. Lambertsen KL, Soares CB, Gaist D, Nielsen HH. Neurofilaments: the C-reactive protein of neurology. Brain Sci 2020; 10: 1-29.
30. Lekomtseva Y, Voloshyn-Gaponov I, Gorbach T. Targeting higher levels of tau protein in Ukrainian patients with Wilson’s disease. Neurol Ther 2019; 8: 59-68.
31. Lin J, Zheng Y, Liu Y, Lin Y, Wang Q, Lin XH et al. Higher concentration of plasma glial fibrillary acidic protein in Wilson disease patients with neurological manifestations. Mov Disord 2021; 36(6): 1446-1450.
32. Litwin T, Gromadzka G, Członkowska A, Gołębiowski M, Poniatowska R. The effect of gender on brain MRI pathology in Wilson’s disease, Metab. Brain Dis 2013; 28: 69-75.
33. Litwin T, Dzieżyc K, Karliński M, Chabik G, Czepiel W, Członkowska A. Early neurological worsening in patients with Wilson’s Diseases. J Neurol Sci 2015; 355: 162-7.
34. Litwin T, Dusek P, Czlonkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol 2017; 142: 211-23.
35. Litwin T, Dusek P, Szafrański T, Dzieżyc K, Członkowska A, Rybakowski JK. Psychiatric manifestations in Wilson’s disease: possibilities and difficulties for treatment. Ther Adv Psychopharmacol 2018; 8: 199-211.
36. Litwin T, Dzieżyc K, Czlonkowska A. Wilson disease – treatment perspectives. Ann. Transl Med 2019; 7: S68.
37. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015; 84: 2247-57.
38. Medici V, Mirante VG, Fassati LR, Pompili M, Forti D, Del Gaudio M et al. Liver transplantation for Wilson’s disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005; 11: 1056-63.
39. Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H. Cranial MRI in Wilson’s disease. Neuroradiology 1990; 32: 211-214.
40. . Poujois A, Sobesky R, Meissner WG, Brunet AS, Broussolle E, Laurencin C et al. Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. Neurology 2020; 94: e2189–202.
41. Rędzia-Ogrodnik B, Członkowska A, Bembenek J, Antos A, Kurkowska-Jastrzębska I, Skowrońska M et al. Brain magnetic resonance imaging and severity of neurological disease in Wilson’s disease – the neuroradiological correlations. Neurol Sci. 2022: 43: 4405-4412.
42. Schilsky ML. Long-term outcome for Wilson disease: 85% good. Clin. Gastroenterol. Hepatol 2014; 12: 690-1.
43. Shribman S, Heller C, Burrows M, Heslegrave A, Swift I, Foiani MS et al. Plasma neurofilament light as a biomarker of neurological involvement in Wilson’s disease. Mov Disord 2021; 36: 50-8. (a)
44. Shribman S, Poujois A, Bandmann O, Czlonkowska A, Warner TT. Wilson’s disease: update on pathogenesis, biomarkers and treatments. J Neurol Neurosurg Psychiatry 2021; 92: 1053-1061. (b)
45. Shribman S, Bocchetta M, Sudre CH, Acosta-Cabronero J, Burrows M, Cook P et al. Neuroimaging correlates of brain injury in Wilson’s disease: a multimodal, whole-brain MRI study. Brain 2022; 29; 145(1): 263-275.
46. Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK. Sequential MRI changes in Wilson’s disease with de-coppering therapy: a study of 50 patients. Br J Radiol 2007; 80: 744-749.
47. Smoliński L, Litwin T, Redzia-Ogrodnik B, Dziezyc K, Kurkowska-Jastrzebska I, Czlonkowska A. Brain volume is related to neurological impairment and to copper overload in Wilson’s disease. Neurological Sciences 2019; 40: 2089-2095.
48. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS 2010; 5: 463-466.
49. Südmeyer M, Saleh A, Wojtecki L, Cohnen M, Gross J, Ploner M et al. Wilson’s disease tremor is associated with magnetic resonance imaging lesions in basal ganglia structures, Mov Disord 2006; 21: 2134-2139.
50. Tarnacka B, Szeszkowski W, Gołebiowski M, Członkowska A. MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord 2008; 23: 1560-1566.
51. Volpert HM, Pfeiffenberger J, Gröner JB, Stremmel W, Gotthardt DN, Schäfer M et al. Comparative assessment of clinical rating scales in Wilson’s disease. BMC Neurology 2917; 17: 140.
52. Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson’s disease. Ann N Y Sci 2014; 1315: 81-5.
53. Weiss KH, Askari FK, Członkowska A, Ferenci P, Bronstein JM, Bega D et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2017; 2: 869-876.
54. Yang J, Huang Z, Yang H, Luo Y, You H, Chen D et al. Plasma neurofilament light chain as a biomarker in Wilson’s disease. Parkinsonism and Related Disorders 2022; 95: 5-10.
55. Ziemssen T, Akgun K, Członkowska A, Antos A, Bembenek J, Kurkowska-Jastrzębska I et al. Serum neurofilament light chain as a biomarker of brain injury in Wilson’s disease: Clinical and neuroradiological correlations. Mov Disord 2022; 37: 1074-1079. (a)
56. Ziemssen T, Smolinski L, Czlonkowska A, Akgun K, Antos A, Bembenek J et al. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease. Acta Neurologica Belgica 2022, doi: 10.1007/s13760-022-02091-z. (b)

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.